Netscientific Share Discussion Threads

[loafofbread] 06/3/2024 21:26

Some nice buying has been going on for the past few weeks.

Hopefully the calm before the news storm!

[loafofbread] 03/3/2024 18:36

Assume we will get an update on the Heat Pump prior to the start of Future build on Tuesday?

Ventive is back showing our full suite of Building Services products: Intelligent Ventilation, Heating and Cooling solutions that autonomously react to the environment - creating comfort without costing the Earth.

We will be unveiling our latest all-in-one Heat Pump, following years of development and welcome you to come and meet the team behind this innovative technology.

From last years fundraise.

The proceeds of the Investment will support the completion of the design and test phase and factory build for Ventive's modular heat pumps, further enhancements to its passive air ventilation product range, and build-up of its marketing and sales capacity to drive sales of its existing product range. The Ventive balance sheet is also streamlined following the conversion of the convertible loans.
Following completion of the Investment, the total equity holding of the NetScientific group in Ventive is 11.0% on a fully diluted basis, which includes the partial settlement of its corporate finance fees relating to the Investment. This holding equates to a post-investment fair value of GBP893,000, a substantial increase of 1,617% from the GBP52,000 reported as at 31 December 2022. In addition, following the introduction of investors to Ventive by EMV Capital under its capital efficient model, NetScientific's capital under advisory with Ventive is now 23.8% of the fully diluted share capital.
Ventive designs and manufactures intelligent heating and ventilation solutions to make buildings healthy, comfortable, efficient, and affordable. Its products address two high priority markets segments: air quality and sustainable heating.
Ventive's passive air ventilation system has been delivered to over 30 schools and five leisure centres, achieving excellent air quality results. Its novel heat pump product, which is in advanced stages of development, is a comprehensive solution for residential applications, with a unique modular design and a novel thermal store. Momentum for the business is underpinned by significant regulatory changes, increasing energy prices, and climate change policies.

[blakieboy7] 01/3/2024 17:16

PDSB near term milestones - htTps://twitter.com/pharmdabbler/status/1763582593268633818?s=46&t=6YXZ4mtuJUFbALPg2zP-ew

[blakieboy7] 01/3/2024 13:55

PDSB looks primed to continue going up today.

[blakieboy7] 01/3/2024 09:30

What's the source Loaf?

[loafofbread] 01/3/2024 09:28

Just out.

February Portfolio & Investment News

Throughout February, the EMV Capital and NetScientific PLC group have seen further developments in its deep tech and life sciences portfolio, and continue building a robust team:

▶ EMV Capital has strengthened its operational team with several new hires, including Andrew Maylor as Consulting Associate, Josh Smith as Private Client Manager, and Selina Frost as Client Services Manager.
▶ Q-Bot Ltd has welcomed John Burley as its new CTO to advance the use of robotics, digital and AI in the retrofit and construction sectors.
▶ ProAxsis has welcomed Matthew Blow as its new Head of Commercial and Business Development. The company is now expediting its Point of Care range in the $5.8 billion global respiratory disease testing market.
▶ PointGrab has welcomed Nathan Toms as its new Sales Director overseeing EMEA and North America.
▶ SageTech Medical has made further progress in commercial discussions in the European human and UK veterinary markets.
▶ Dr ILIAN ILIEV, MD of EMV Capital, participated in the Verbier ConstructionTech Summit 2024 focused on the future of construction and sustainability. With presentations from Q-Bot Ltd and Ventive Limited, the event was organised by our partners Shibumi International and IMPULSE PARTNERS - A FAST LANE FOR INNOVATION.
▶ Edward Hooper, Director of EMV Capital, participated in a panel discussion at the British Private Equity & Venture Capital Association (BVCA) First-Time Fundraising Forum on 29 February, providing valuable insight into raising funds from LPs.
▶ EMV Capital is now directly authorised and regulated by the Financial Conduct Authority with firm reference number 982590.

[btgman] 01/3/2024 08:57

With pdsb worth over £7m of NSCI market cap we are sat at circa 1/3 of net asset value.

Trading statement due in next month or so this one will be fascinating

AIMHO
GLA
BTG

[blakieboy7] 29/2/2024 19:19

Agreed loaf - pdsb up over 12% so far

[loafofbread] 29/2/2024 19:12

Looks like another massive 2M plus volume day at PDSB.

Over $20M up on the day, so £800k to NSCI and we actually went down.

I am so looking forward to the day that PDSB just goes vertical and we double on the news.

AIM and the UK market in general is the worst I have ever seen in 30 years.

[btgman] 29/2/2024 15:32

Yes pdsb up NSCI down that makes perfect sense in the upside world we live in.

This will turn at some point results can't be too far away

AIMHO
GLA
BTG

[blakieboy7] 29/2/2024 14:41

PDSB up again today

[blakieboy7] 28/2/2024 09:53

We need some Simon Thomson commentary

[loafofbread] 27/2/2024 23:50

Insane volume/strength with PDSB tonight and still going strong.

£800K gain to NSCI if anyone is counting.

[btgman] 27/2/2024 15:41

UK market is absolute insanity just totally ignoring fundamental shifts in value pdsb circa £7.2m of market cap the discount just keeps getting wider. Buying at less than 33% of NAV is madness

AIMHO
GLA
BTG

[blakieboy7] 27/2/2024 14:54

PDS biotech up over 8% already

[loafofbread] 20/2/2024 22:57

ProAxsis announces strenghtening of Board and Update on Strategy

To expedite Point of Care range in respiratory diagnostics


ProAxsis Limited, the Belfast-based diagnostics company in respiratory disease, is pleased to announce that is has strengthened its Board and updated its corporate strategy in line with its next phase of growth and market opportunities.

Described as the ‘’gold standard in respiratory research’̵7; by pharmaceutical company partners, ProAxsis develops and supplies diagnostic assays, using biomarkers that aid clinical trials and clinical intervention and potentially lead to improved patient outcomes in various respiratory disease areas including Chronic Obstructive Pulmonary Disease (COPD), Bronchiectasis and Cystic Fibrosis. Building on its progress to date with leading pharmaceutical companies, including Insmed, Hölzel Diagnostika and Boehringer Ingelheim, the company is now well placed to intensify its efforts in the patient Point of Care (POC) product range.

The patient POC application will combine its patented NEATstik® with an integrated Remote Patient Monitoring platform to enhance patient outcomes, while delivering unparalleled value to healthcare providers. To that end, the company has strengthened its leadership team with relevant executive experience and is refocusing its resources to unlock the next stage of growth in the $5.8 billion global respiratory disease testing market.1

Appointment of new Chairperson and Non-Executive Director

ProAxsis has appointed Alan Markey as its Chairperson. Alan brings significant expertise in MedTech to the company, having accumulated over 25 years of senior executive experience in the pharmaceutical and medical device sectors globally. Alan’s career spans senior roles at Johnson & Johnson, and Wyeth Pharmaceuticals (acquired by Pfizer). He has also served as MD of Baxter Healthcare, CEO of Noden Pharma DAC, and is a former Chairperson of HealthTech Ireland. His industry expertise and contacts will contribute significantly to the company’s strategy implementation.

ProAxsis is also delighted to introduce Professor Steven Myint as a Non-Executive Director to the Board. Professor Myint is an internationally experienced Clinician, with past roles including Medical Director at GlaxoSmithKline and Senior Vice-President for R&D/Chief Medical Officer at BTG International. After his own first university spinout in 2005, he has been involved in the development of over 20 SMEs in life sciences and created over $1 billion value for shareholders. He is also a visiting Professor at the University of Surrey. Professor Myint’s insights and strategic guidance will be invaluable in shaping ProAxsis’s future.

ProAxsis also announces that David Ribeiro, Chief Executive Officer, will be stepping down after nine years with the company to pursue another opportunity.

The company continues to draw on the services and support of its key investor NetScientific PLC, a deep tech and life sciences VC investment group with an international portfolio of innovative companies. The company’s reorientation has further been supported by the investment facilitated by EMV Capital, the venture capital arm of NetScientific.

Strategic Shift

The global investment and international pharmaceutical company interest into respiratory diseases continues to grow alongside a drive for convenience, accelerated by the coronavirus pandemic. COPD is the third leading cause of death worldwide, and COPD cases are expected to grow from 480 million in 2020 to 660 million by 20502. In the UK alone, lung disease alone costs more than £11 billion per year, including the impact on the NHS (£9.9bn), and wider economy through working days lost (£1.2bn)3.

ProAxsis is committed to remaining at the forefront of major developments and with its strategic shift towards Point of Care Testing (POCT), the company is bringing testing conveniently to the patient, potentially improving patient outcomes, clinician experience, and driving down healthcare costs to governments and insurance providers.

The POCT will employ the company’s proprietary NEATstik technology to offer patients and healthcare providers novel solutions to prioritise patients with the highest immediate need. This will empower healthcare professionals to make quicker and more informed decisions and will enhance patient outcomes by: minimising avoidable exacerbations, reducing unnecessary clinic visits, and cutting down on extended hospital stays.

The company intends to seek strategic alliances that will enable greater investment towards the development and expedited launch of its Patient Platform.

Alan Markey, the new Chairperson of ProAxsis, commented:

“I am honoured to join ProAxsis as Chairman during this exciting moment in the company’s journey. With a strong foundation in respiratory disease diagnostics and a renewed strategic focus on patient Point of Care testing, ProAxsis is poised to make further significant impact in improving patient outcomes and delivering value to healthcare providers.

The Board extends gratitude to David for his leadership, dedication, and valuable contributions during his tenure, wishing him every success for the future. I look forward to working closely with the Board and wider management team to drive these initiatives and contribute to ProAxsis’s continued success.”

Professor Steven Myint, the new Non-Executive Director of ProAxsis, added:

“I am privileged to join ProAxsis as a Non-Executive Director and look forward to contributing my clinical and strategic insights to advance the company’s mission of improving patient outcomes in respiratory diseases. Through our focus on patient Point of Care Testing, powered by innovative and patented technology, we aim to empower healthcare providers with timely and accurate diagnostic solutions, ultimately enhancing patient care and quality of life.”

[loafofbread] 20/2/2024 17:45

Nice delayed buy/trade for 35000 shares @ 72p.

[loafofbread] 20/2/2024 09:26

Looking forward to seeing these deals announced.

Following the Investment and conversion of the 2023 CLA (assuming all accrued interest is converted), the Company's direct stake in Glycotest will be 55.90 per cent, alongside Fosun's interest of 34.75 per cent. and the 2023 CLA interest of 6.16 per cent.

The proceeds of the Investment will, inter alia, support Glycotest in the development and validation of its assays ahead of commercial launch. Such validation is possible after the completion in 2023 of subject enrolment and sample collection in Glycotest's clinical validation study, providing a valuable biobank which the company believes now represents one of the world's largest collections of liver cancer blood samples. Glycotest is in advanced negotiations with a number of prospective collaboration partners, further details of which shall be reported in due course.

[btgman] 19/2/2024 14:53

I am very relaxed with NSCI it is a matter of when not if. Their underlying assets are multiples of current share price. Very little stock around on this one. I doubt whatever is around is going to last very long.

AIMHO
GLA
BTG

[blakieboy7] 19/2/2024 08:17

The spread has closed nicely too

[loafofbread] 19/2/2024 08:06

Even the chart is looking good for a continued rise.

If we can just get past the stale 67p {last placing )it is blue sky time.

Must be close to some PDSB news which could add a few pence!

[blakieboy7] 15/2/2024 08:07

Goodness know we need an RNS of some description! It's been ages

[loafofbread] 15/2/2024 08:04

Over the past week, Proaxis has updated it's website again.

Also managed it's first post in over 8 months (as far as I can tell)

Might be the start of something?